|
1
|
Stewart C, Ralyea C and Lockwood S:
Ovarian Cancer: An integrated review. Semin Oncol Nurs. 35:151–156.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Trabert B, DeSantis CE, Miller
KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A and Siegel RL:
Ovarian cancer statistics, 2018. CA Cancer J Clin. 68:284–296.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Peng WX, Koirala P and Mo YY:
LncRNA-mediated regulation of cell signaling in cancer. Oncogene.
36:5661–5667. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li Z, Lu Q, Zhu D, Han Y, Zhou X and Ren
T: Lnc-SNHG1 may promote the progression of non-small cell lung
cancer by acting as a sponge of miR-497. Biochem Biophys Res
Commun. 506:632–640. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lei K, Liang X, Gao Y, Xu B, Xu Y, Li Y,
Tao Y, Shi W and Liu J: Lnc-ATB contributes to gastric cancer
growth through a miR-141-3p/TGFβ2 feedback loop. Biochem Biophys
Res Commun. 484:514–521. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ge YW, Gao HM and Wang ZM: Advances in
study of genus curcuma. Zhongguo Zhong Yao Za Zhi. 32:2461–2467.
2007.(In Chinese). PubMed/NCBI
|
|
7
|
Li ZT, Zhang X, Wang DW, Xu J, Kou KJ,
Wang ZW, Yong G, Liang DS and Sun XY: Overexpressed lncRNA
GATA6-AS1 Inhibits LNM and EMT via FZD4 through the Wnt/β-catenin
signaling pathway in GC. Mol Ther Nucleic Acids. 19:827–840. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Catela Ivkovic T, Voss G, Cornella H and
Ceder Y: microRNAs as cancer therapeutics: A step closer to
clinical application. Cancer Lett. 407:113–122. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen QQ, Shi JM, Ding Z, Xia Q, Zheng TS,
Ren YB, Li M and Fan LH: Berberine induces apoptosis in
non-small-cell lung cancer cells by upregulating miR-19a targeting
tissue factor. Cancer Manag Res. 11:9005–9015. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu Y, Liu R, Yang F, Cheng R, Chen X, Cui
S, Gu Y, Sun W, You C, Liu Z, et al: miR-19a promotes colorectal
cancer proliferation and migration by targeting TIA1. Mol Cancer.
16:532017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang Y, Zhao S, Zhu L, Zhang Q and Ren Y:
miR-19a negatively regulated the expression of PTEN and promoted
the growth of ovarian cancer cells. Gene. 670:166–173. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang B, Liu Y and Zhang J: Silencing of
miR-19a-3p enhances osteosarcoma cells chemosensitivity by
elevating the expression of tumor suppressor PTEN. Oncol Lett.
17:414–421. 2019.PubMed/NCBI
|
|
13
|
Ren S and Xu Y: AC016405.3, a novel long
noncoding RNA, acts as a tumor suppressor through modulation of
TET2 by microRNA-19a-5p sponging in glioblastoma. Cancer Sci.
110:1621–1632. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Alven S and Aderibigbe BA: Nanoparticles
formulations of artemisinin and derivatives as potential
therapeutics for the treatment of cancer, leishmaniasis and
malaria. Pharmaceutics. 12:7482020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sheng J, Wang L, Han Y, Chen W, Liu H,
Zhang M, Deng L and Liu YN: Dual roles of protein as a template and
a sulfur provider: A general approach to metal sulfides for
efficient photothermal therapy of cancer. Small. Nov 17–2017.(Epub
ahead of print). doi: 10.1002/smll.201702529.
|
|
16
|
Wang P, Wang J, Tan H, Weng S, Cheng L,
Zhou Z and Wen S: Acid- and reduction-sensitive micelles for
improving the drug delivery efficacy for pancreatic cancer therapy.
Biomater Sci. 6:1262–1270. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu
J, Xu ZD, Zhu HG, Ling ZQ, Ye D, et al: Tumor development is
associated with decrease of TET gene expression and
5-methylcytosine hydroxylation. Oncogene. 32:663–669. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tucker DW, Getchell CR, McCarthy ET, Ohman
AW, Sasamoto N, Xu S, Ko JY, Gupta M, Shafrir A, Medina JE, et al:
Epigenetic reprogramming strategies to reverse global loss of
5-hydroxymethylcytosine, a prognostic factor for poor survival in
high-grade serous ovarian cancer. Clin Cancer Res. 24:1389–1401.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang LY, Li PL, Wang TZ and Zhang XC:
Prognostic values of 5-hmC, 5-mC and TET2 in epithelial ovarian
cancer. Arch Gynecol Obstet. 292:891–897. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zou MF, Ling J, Wu QY and Zhang CX: Long
non-coding RNA PVT1 functions as an oncogene in ovarian cancer via
upregulating SOX2. Eur Rev Med Pharmacol Sci.
24:75712020.PubMed/NCBI
|
|
22
|
Martini P, Paracchini L, Caratti G,
Mello-Grand M, Fruscio R, Beltrame L, Calura E, Sales G, Ravaggi A,
Bignotti E, et al: lncRNAs as novel indicators of patients'
prognosis in stage I epithelial ovarian cancer: A retrospective and
multicentric study. Clin Cancer Res. 23:2356–2366. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xie T, Wu D, Li S, Li X, Wang L, Lu Y,
Song Q, Sun X and Wang X: microRNA-582 potentiates liver and lung
metastasis of gastric carcinoma cells through the FOXO3-mediated
PI3K/Akt/Snail pathway. Cancer Manag Res. 12:5201–5212. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ni WJ and Leng XM: miRNA-dependent
activation of mRNA Translation. Microrna. 5:83–86. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Deb B, Uddin A and Chakraborty S: miRNAs
and ovarian cancer: An overview. J Cell Physiol. 233:3846–3854.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xiang G and Cheng Y: miR-126-3p inhibits
ovarian cancer proliferation and invasion via targeting PLXNB2.
Reprod Biol. 18:218–224. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu ZH, Yao TZ and Liu W: miR-378a-3p
sensitizes ovarian cancer cells to cisplatin through targeting
MAPK1/GRB2. Biomed Pharmacother. 107:1410–1417. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang CB, Xiao SW, Cheng SM and Zhang C:
LncRNA FAS-AS1 inhibits the progression of non-small cell lung
cancer through regulating miR-19a-5p. Eur Rev Med Pharmacol Sci.
24:3775–3785. 2020.PubMed/NCBI
|
|
29
|
Liu GM, Lu TC, Sun ML, Ji X, Zhao YA, Jia
WY and Luo YG: RP11-874J12.4 promotes oral squamous cell carcinoma
tumorigenesis via the miR-19a-5p/EBF1 axis. J Oral Pathol Med.
49:645–654. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sun HX, Yang ZF, Tang WG, Ke AW, Liu WR,
Li Y, Gao C, Hu B, Fu PY, Yu MC, et al: MicroRNA-19a-3p regulates
cell growth through modulation of the PIK3IP1-AKT pathway in
hepatocellular carcinoma. J Cancer. 11:2476–2484. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Su YF, Zang YF, Wang YH and Ding YL:
miR-19-3p induces tumor cell apoptosis via targeting FAS in rectal
cancer cells. Technol Cancer Res Treat. 19:15330338209179782020.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ko M, An J, Pastor WA, Koralov SB,
Rajewsky K and Rao A: TET proteins and 5-methylcytosine oxidation
in hematological cancers. Immunol Rev. 263:6–21. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chiba S: Dysregulation of TET2 in
hematologic malignancies. Int J Hematol. 105:17–22. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ko M, Huang Y, Jankowska AM, Pape UJ,
Tahiliani M, Bandukwala HS, An J, Lamperti ED, Koh KP, Ganetzky R,
et al: Impaired hydroxylation of 5-methylcytosine in myeloid
cancers with mutant TET2. Nature. 468:839–843. 2010. View Article : Google Scholar : PubMed/NCBI
|
